Parkinson's Disease: Pathophysiology, Symptoms, Comprehensive Treatment Plan and Dual Approach of Bromocriptine in Parkinson’s Disease and Diabetes Mellitus

Abstract

In addition to a wide range of non-motor symptoms that impair a patient's quality of life, Parkinson's disease (PD) is a chronic and progressive neurodegenerative illness that is primarily defined by motor symptoms such bradykinesia, stiffness, and tremor. Parkinson's disease (PD) upsets the balance of neurotransmitters necessary for coordinated motor activity and is caused by the progressive loss of dopaminergic neurons in the substantia nigra. This study explores the intricate pathophysiology of Parkinson's disease (PD), looking at the functions of Lewy bodies, genetic variables like SNCA and LRRK2 mutations, and environmental factors including mitochondrial malfunction and oxidative stress. In addition to these insights, we list the main motor and non-motor symptoms that affect therapy methods and provide diagnostic issues, ranging from autonomic disturbances to postural instability and cognitive deterioration. Since there is presently no known cure or method to stop the progression of the disease, treatment for Parkinson's disease (PD) focuses on managing symptoms with pharmacologic and non-pharmacologic therapies. Dopamine agonists, MAO-B inhibitors, and dopamine replacement therapy especially Levodopa are the principal treatments. Drug effectiveness, however, may wane with time, and long-term care is frequently complicated by motor fluctuations and dyskinesias. The dual therapeutic role of bromocriptine, a dopamine agonist that has historically been used to treat motor symptoms in Parkinson's disease (PD), is particularly noteworthy. It also shows promise for glycemic management in those with concomitant type 2 diabetes mellitus (T2DM). By altering central neuroendocrine rhythms, bromocriptine's special mechanism improves insulin sensitivity, lowers plasma glucose levels, and may even lessen cardiovascular risk in diabetic individuals. Both neurological and metabolic issues may be addressed by this dual-method treatment, offering a customized way to handling challenging situations. With a focus on the growing use of bromocriptine for diabetic patients, this study attempts to present a thorough analysis of the pathogenesis, symptomatology, and available treatments for Parkinson's disease. We stress the need for a customized treatment plan and the significance of routinely checking for adverse effects, especially in patients using dopamine agonists and other adjunct medicines. We demonstrate the potential to improve life quality for people juggling the combined difficulties of diabetes mellitus and Parkinson's disease by incorporating bromocriptine into the treatment paradigm.